Correction to:Efficacy, safety and drug survival of thioguanine as maintenance treatment for inflammatory bowel disease: a retrospective multi-centre study in the United Kingdom (BMC Gastroenterology, (2020), 20, 1, (296), 10.1186/s12876-020-01441-6)

Autor: Bayoumy, Ahmed B., van Liere, Elsa L.S.A., Simsek, Melek, Warner, Ben, Loganayagam, Aathavan, Sanderson, Jeremy D., Anderson, Simon, Nolan, Jonathan, de Boer, Nanne K., Mulder, Chris J.J., Ansari, Azhar
Přispěvatelé: Gastroenterology and hepatology, Amsterdam Gastroenterology Endocrinology Metabolism
Jazyk: angličtina
Rok vydání: 2022
Zdroj: Bayoumy, A B, van Liere, E L S A, Simsek, M, Warner, B, Loganayagam, A, Sanderson, J D, Anderson, S, Nolan, J, de Boer, N K, Mulder, C J J & Ansari, A 2022, ' Correction to : Efficacy, safety and drug survival of thioguanine as maintenance treatment for inflammatory bowel disease: a retrospective multi-centre study in the United Kingdom (BMC Gastroenterology, (2020), 20, 1, (296), 10.1186/s12876-020-01441-6) ', Bmc Gastroenterology, vol. 22, no. 1, 208 . https://doi.org/10.1186/s12876-021-01992-2
Bmc Gastroenterology, 22(1):208. BioMed Central
ISSN: 1471-230X
DOI: 10.1186/s12876-020-01441-6)
Popis: After publication of this article [1], the authors reported three adjustments: 1. Competing interests: the travel grants were paid by HLW Pharma instead of TEVA Pharma. 2. TGN-units all over the manuscript have to be adjusted from pmol/8 × 105 RBC to pmol/8 × 108 RBC. 3. Some minor textual adjustments. The original article [1] has been updated.
Databáze: OpenAIRE
Externí odkaz: